Edgar Filing: WATSON PHARMACEUTICALS INC - Form 4

WATSON PH Form 4 May 12, 2008	ARMACEUTIC	ALS INC									
FORM	4								• · · · • · ·	PPROVAL	
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Check this box if no longer subject to Section 16. Form 4 or						COMMISSION	OMB Number:	3235-0287		
if no longer subject to Section 16.								Estimated average burden hours per			
Form 5 obligations may continu <i>See</i> Instruct 1(b).	ue. Section 17(a)	of the Pub		Holdi	ng Com	pany	Act o	ge Act of 1934, f 1935 or Sectio 40			
(Print or Type Res	sponses)										
HUMMEL ALBERT F Symbol WATS			mbol	ISON PHARMACEUTICALS				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) 131 RIDGEFI	(Last) (First) (Middle) 3. Date of			of Earliest Transaction /Day/Year) 2008				X_ Director 10% Owner Officer (give title Other (specify below) below)			
Filed(Mont				nendment, Date Original onth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
	SQUARE, PA 19	9073						Person		porting	
(City)	(State) (Z	Cip)	Table I - I	Non-De	rivative S	ecuri	ties Aco	quired, Disposed o	f, or Beneficial	ly Owned	
	Security (Month/Day/Year) Execution Date, if		Date, if Tra	3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A)			Securities Beneficially Owned Following Reported	6. Ownership Form: Direct D) or Indirect (I) Instr. 4)			
Common			Co	ode V	Amount	or (D)	Price	Transaction(s) (Instr. 3 and 4)			
Stock, par value \$0.0033	05/09/2008		A	A	5,000 (1)	А	\$0	159,514 <u>(2)</u>	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3,	;	Date	Amou Under Secur	le and unt of rlying ities (1, 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
				Code V	4, and 5)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: WATSON PHARMACEUTICALS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	\$	Relationships						
	Director	10% Owner	Officer	Other				
HUMMEL ALBERT F 131 RIDGEFIELD ROAD NEWTOWN SQUARE, PA 190	X)73							
Signatures								
/s/ALBERT F. HUMMEL	05/09/2008							
**Signature of Reporting Person	Date							

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- These restricted shares of common stock, par value \$0.0033, were issued pursuant to the provisions of the Second Amendment and(1) Restatement of the 2001 Incentive Award Plan of Watson Pharmaceuticals, Inc. and will vest 100% on the first anniversary of the date of grant.
- (2) Includes shares of restricted stock issued pursuant to the Second Amendment and Restatement of the 2001 Incentive Award Plan of Watson Pharmaceuticals, Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.